Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19

  10 April 2020

As America’s biopharmaceutical companies work around the clock to combat COVID-19, a disease caused by a novel strain of coronavirus, now is an important time to consider how we can prepare for the next public health emergency: Antimicrobial resistance (AMR). AMR occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that make the medications used to cure the infections they cause ineffective. According to the Centers for Disease Control and Prevention (CDC), more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. A key facet to fighting AMR is to ensure prescriber education to support appropriate prescribing of antibiotics.

We recently spoke with Dr. Julie Gerberding, executive vice president and chief patient officer at Merck, about AMR and the biopharmaceutical industry’s efforts to combat the COVID-19 pandemic. Prior to joining Merck, Dr. Gerberding served as director for the CDC where she led the response for public health emergencies and disease outbreaks. The following interview has been edited and condensed for clarity and length.

Further reading: The Catalyst
Author(s): Andrew Powaleny
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed